{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:44:34Z","timestamp":1780533874984,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this article is to investigate the prevalence of systemic lupus erythematosus (SLE) in Japan and explore its treatment regimens in different age groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified patients with SLE from the National Database of Health Insurance Claims of anonymized health insurance-related information; they had disease names associated with SLE and were treated with glucocorticoids, hydroxychloroquine, or immunosuppressants. These data were used to investigate disease prevalence and profiles in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 74,277 patients with SLE, 12,816 were men (16.6%) and 61,961 were women (83.4%). Oral glucocorticoids were administered to 89.1% of patients and hydroxychloroquine to 21.4%. Regarding immunosuppressants, mycophenolate mofetil was prescribed for 49.2% of patients aged \u226414\u2009years and tacrolimus for 35.5% of those aged 20\u201339\u2009years; these rates were higher than those observed in other age groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The high proportion of patients receiving treatment for comorbidities may be partially explained by the high rate of glucocorticoid use, as approval of hydroxychloroquine for the treatment of SLE was delayed in Japan. This is the first study to ascertain the prevalence of SLE and its treatment status in Japan using the National Database, thus providing useful basic data to improve the management of the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roaf020","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:34:24Z","timestamp":1741685664000},"page":"850-858","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-5778","authenticated-orcid":false,"given":"Masakazu","family":"Matsushita","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical University , Tokyo,","place":["Japan"]},{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-443X","authenticated-orcid":false,"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-7772","authenticated-orcid":false,"given":"Masaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-687X","authenticated-orcid":false,"given":"Yuzaburo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of General Medical Science, Graduate School of Medicine, Chiba University , Chiba,","place":["Japan"]},{"name":"Department of Allergy and Rheumatology, Chiba Children\u2019s Hospital , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]},{"name":"Showa University Research Administration Center, Showa University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamaji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-4866","authenticated-orcid":false,"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-1496","authenticated-orcid":false,"given":"Takako","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2025090306271992500_R1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/ard-2023-225319","article-title":"Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations","volume":"83","author":"Kostopoulou","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090306271992500_R2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/kead348","article-title":"Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality \u2013 a national cohort study","volume":"63","author":"Frodlund","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090306271992500_R3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/1744666X.2023.2294938","article-title":"Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus","volume":"20","author":"Paredes-Ruiz","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090306271992500_R4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090306271992500_R5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090306271992500_R6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025090306271992500_R7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2025090306271992500_R8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","article-title":"Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition","volume":"195","author":"Torigoe","year":"2018","journal-title":"Clin Immunol"},{"key":"2025090306271992500_R9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/mr\/roac113","article-title":"Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment","volume":"33","author":"Shimizu","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025090306271992500_R10","doi-asserted-by":"crossref","DOI":"10.1186\/ar3378","article-title":"Lupus nephritis: current update","volume":"13","author":"Saxena","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090306271992500_R11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/09612033211021163","article-title":"Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy","volume":"30","author":"Sen","year":"2021","journal-title":"Lupus"},{"key":"2025090306271992500_R12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.afos.2020.11.001","article-title":"Prevalence of osteoporosis in patients with systemic lupus erythematosus: a multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria","volume":"6","author":"Jung","year":"2020","journal-title":"Osteoporos Sarcopenia"},{"key":"2025090306271992500_R13","article-title":"Delayed global standardization and prefectural disparities in systematic lupus erythematosus treatment in Japan: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"21","author":"Yokogawa","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025090306271992500_R14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.31662\/jmaj.2023-0078","article-title":"Literature review of studies using the National Database of the Health Insurance Claims of Japan (NDB): limitations and strategies in using the NDB for research","volume":"7","author":"Suto","year":"2024","journal-title":"JMA J"},{"key":"2025090306271992500_R15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.37737\/ace.23008","article-title":"A review of studies using Japanese nationwide administrative claims databases","volume":"5","author":"Sato","year":"2023","journal-title":"Ann Clin Epidemiol"},{"key":"2025090306271992500_R16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40801-022-00331-5","article-title":"A review of research studies using data from the administrative claims databases in Japan","volume":"9","author":"Fujinaga","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2025090306271992500_R17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.31662\/jmaj.2022-0184","article-title":"Studies of health insurance claims data in Japan: a scoping review","volume":"6","author":"Suto","year":"2023","journal-title":"JMA J"},{"key":"2025090306271992500_R18","first-page":"32","article-title":"International statistical classification of diseases and related health problems. Tenth revision","volume":"41","author":"Br\u00e4mer","year":"1988","journal-title":"World Health Stat Q"},{"key":"2025090306271992500_R19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2016.08.001","article-title":"The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned","volume":"74","author":"Teruel","year":"2016","journal-title":"J Autoimmun"},{"key":"2025090306271992500_R20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"2025090306271992500_R21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2176\/nmc.st.2016-0135","article-title":"National registry of designated intractable diseases in Japan: present status and future prospects","volume":"57","author":"Kanatani","year":"2017","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2025090306271992500_R22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CM9.0000000000002360","article-title":"Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII","volume":"135","author":"Gui","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"2025090306271992500_R23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025090306271992500_R24","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1210\/jcem.83.8.5036","article-title":"Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study","volume":"83","author":"Allen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090306271992500_R25","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000817","article-title":"Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA","volume":"10","author":"Brunner","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025090306271992500_R26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/s10165-011-0503-y","article-title":"Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI)","volume":"22","author":"Yokogawa","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2025090306271992500_R27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1346-8138.2011.01448.x","article-title":"Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study","volume":"39","author":"Ikeda","year":"2012","journal-title":"J Dermatol"},{"key":"2025090306271992500_R28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/1346-8138.12005","article-title":"Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus","volume":"40","author":"Momose","year":"2013","journal-title":"J Dermatol"},{"key":"2025090306271992500_R29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10384-021-00841-9","article-title":"Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment","volume":"65","author":"Ozawa","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"2025090306271992500_R30","doi-asserted-by":"crossref","DOI":"10.3109\/15569527.2013.781619","article-title":"Screening for hydroxychloroquine toxicity in children","volume":"32","author":"Modjtahedi","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"key":"2025090306271992500_R31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.rdc.2007.01.001","article-title":"Rheumatoid arthritis and reproduction","volume":"33","author":"Golding","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090306271992500_R32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/acr.22000","article-title":"Induced abortions in women with rheumatoid arthritis receiving methotrexate","volume":"65","author":"Vinet","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090306271992500_R33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae168","article-title":"Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study","volume":"64","author":"Nguyen","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090306271992500_R34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae302","article-title":"Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients","volume":"64","author":"Alle","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090306271992500_R35","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-024-00366-y","article-title":"Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study","volume":"64","author":"de Luca Montes","year":"2024","journal-title":"Adv Rheumatol"},{"key":"2025090306271992500_R36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.15585\/mmwr.mm7007a2","article-title":"Mortality among minority populations with systemic lupus erythematosus, including Asian and Hispanic\/Latino persons \u2013 California, 2007\u20132017","volume":"70","author":"Gianfrancesco","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090306271992500_R37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.15585\/mmwr.mm6818a4","article-title":"Racial disparities in mortality associated with systemic lupus erythematosus \u2013 Fulton and DeKalb Counties, Georgia, 2002\u20132016","volume":"68","author":"Lim","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025090306271992500_R38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M17-0102","article-title":"46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study","volume":"167","author":"Yen","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf020\/62375165\/roaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/850\/62375165\/roaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/5\/850\/62375165\/roaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:27:34Z","timestamp":1756895254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/5\/850\/8069427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf020","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,11]]}}}